Application of influenza treating medicine composition in preparation of antiviral medicine
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A composition and antiviral technology, which can be used in drug combinations, medical preparations containing active ingredients, pharmaceutical formulations, etc., can solve the problems of weak effect, inability to determine the effect of the virus, etc., and achieve the effect of reducing mortality
Inactive Publication Date: 2016-02-24
SHANGHAI PHARMA GRP QINGDAO GROWFUL PHARMA CO LTD
View PDF2 Cites 4 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
In December 2013, H1N1 spread to ten states in the United States, killing four children and hospitalizing tens of thousands
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0117] Embodiment 1: the preparation of tablet
[0118] Ephedra 6k, mint 5kg, cicada slough 5kg, honeysuckle 15kg, scutellaria baicalensis 12kg, bitter almond 9kg, Fritillaria 6kg, bellflower 6kg, licorice 5kg; add conventional dressings to make tablets according to conventional methods. It is used to inhibit the reproduction of RSV, EV71, COX-B3, and H1N1 viruses; increase the expression of IFN-γ and IL-2, and reduce the mRNA expression of TNF-α.
Embodiment 2
[0119] Embodiment 2: the preparation of capsule
[0120] Ephedra 3kg, Mint 9kg, Cicada slough 3kg, Honeysuckle 17kg, Scutellaria baicalensis 9kg, Bitter almond 16kg, Fritillaria 3kg, Campanulaceae 8kg, Licorice 4kg. Add conventional dressings according to conventional methods to make capsules. It is used to inhibit the reproduction of RSV, EV71, COX-B3, and H1N1 viruses; increase the expression of IFN-γ and IL-2, and reduce the mRNA expression of TNF-α.
Embodiment 3
[0121] Embodiment 3: Preparation of oral liquid preparation
[0122] Ephedra 9kg, Mint 2kg, Cicada slough 7kg, Honeysuckle 11kg, Scutellaria baicalensis 18kg, Bitter almond 7kg, Fritillaria 7kg, Campanulaceae 4kg, Licorice 8kg. Add conventional dressings according to conventional methods to make oral liquid preparations. It is used to inhibit the reproduction of RSV, EV71, COX-B3, and H1N1 viruses; increase the expression of IFN-γ and IL-2, and reduce the mRNA expression of TNF-α.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The invention discloses application of an influenza treating medicine composition in preparation of antiviral medicine. The medicine composition is prepared from, by weight, 1-9 parts of ephedra, 1-9 parts of mint, 1-9 parts of periostracum cicada, 1-20 parts of honeysuckles, 2-20 parts of scutellaria baicalensis, 2-18 parts of semen armeniacae amarae, 1-9 parts of thunberg fritillary bulb, 1-9 parts of platycodon grandiflorum and 1-9 parts of liquorice. The raw materials are taken, conventional auxiliary materials are added, and clinically-acceptable tablets, granules, pills, capsules, dropping pills, soft capsules, slow-release preparations, oral liquid preparations or freeze-dried powder injections are prepared according to the conventional process; new application is developed, and new medicine is provided for treating infection of viruses RSV, EV71, COX-B3 and H1N1.
Description
technical field [0001] The invention relates to a new application of a medicinal composition for treating colds, in particular to an application of the medicinal composition for treating colds in preparing antiviral medicines. Background technique [0002] H1N1 is an RNA virus belonging to the Orthomyxoviridae family. Its hosts are canids, birds and some mammals. Almost all H1N1 A viruses have been isolated, and disease in wild birds is rare. Some H1N1 viruses cause severe disease mostly in poultry and pets but rarely in humans. But through the spread and mutation of mammals, mainly birds and canines, this could lead to epidemics or widespread spread of human influenza. In December 2013, H1N1 spread to ten states in the United States, killing four children and hospitalizing tens of thousands of adults with little effect. [0003] RSV virus is the abbreviation of Respiratory Syncytial Virus in English, and Chinese means Respiratory Syncytial Virus. RSV is a leading cause...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more